GRAIL (GRAL) Stock Price, News & Analysis

Company Overview

GRAIL, Inc. (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom. From its inception, the company has pursued large-scale clinical programs, including the Circulating Cell-Free Genome Atlas (CCGA) study and the STRIVE study, to validate the performance of its assays in diverse populations. These efforts have driven breakthrough device designations from the U.S. Food and Drug Administration and informed regulatory submissions around the world.

GRAIL collaborates with academic institutions, healthcare systems and research organizations to integrate its technology into clinical pathways. The company has partnerships with leading medical centers and national health services, supporting both observational studies and interventional clinical trials. In addition to its direct-to-physician model, GRAIL is working with payers and health plans to explore reimbursement frameworks that broaden patient access to early-detection screening.

The company is led by a management team of seasoned experts in oncology, genomics and diagnostics, whose combined experience spans biotech innovation and regulatory affairs. With a commitment to data-driven research and global health equity, GRAIL continues to expand its reach, seeking to transform the standard of care for cancer screening and improve outcomes through earlier diagnosis.

Key Stats

• Today's Range: $58.26 to $62.10
• 50-Day Range: $43.06 to $62.92
• 52-Week Range: $29.95 to $118.84
• Volume: 552,934 shs
• Average Volume: 1.07 million shs
• Market Capitalization: $2.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $67.88
• Consensus Rating: Hold

GRAIL Stock Analysis - MarketRank™

GRAIL scored higher than 39% of companies evaluated by MarketBeat, and ranked 688th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

GRAIL has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

GRAIL has a consensus price target of $67.88, representing about 11.3% upside from its current price of $60.99.

Amount of Analyst Coverage

GRAIL has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GRAIL are expected to grow in the coming year, from ($10.91) to ($10.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GRAIL is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GRAIL is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GRAIL has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.57% of the float of GRAIL has been sold short.

Short Interest Ratio / Days to Cover

GRAIL has a short interest ratio ("days to cover") of 13.38, which indicates bearish sentiment.

Change versus previous month

Short interest in GRAIL has recently decreased by 0.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GRAIL does not currently pay a dividend.

Dividend Growth

GRAIL does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.35

News Sentiment

GRAIL has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for GRAIL this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for GRAL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

9 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,485,396.00 in company stock.

Percentage Held by Insiders

1.83% of the stock of GRAIL is held by insiders.

Percentage Held by Institutions

GRAIL has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:GRAL
• Previous Symbol: NASDAQ:GRAL
• CIK: 1699031
• Web: N/A
• Phone: (650) 771-9796
• Fax: N/A
• Employees: 1,360
• Year Founded: 2016

Price Target and Rating

• Average Price Target for GRAIL: $67.88
• High Price Target: $80.00
• Low Price Target: $56.00
• Potential Upside/Downside: +11.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$408.35 million
• Net Margins: -253.22%
• Pretax Margin: -330.27%
• Return on Equity: -16.42%
• Return on Assets: -14.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.74
• Quick Ratio: 11.74

Sales & Book Value

• Annual Sales: $147.17 million
• Price / Sales: 17.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $66.13 per share
• Price / Book: 0.92

Miscellaneous

• Outstanding Shares: 42,920,000
• Free Float: 42,132,000
• Market Cap: $2.62 billion
• Optionable: Optionable
• Beta: 3.03